Front. Pharmacol. Frontiers in Pharmacology Front. Pharmacol. 1663-9812 Frontiers Media S.A. 10.3389/fphar.2014.00233 Pharmacology Mini Review Article Interleukin-12 family cytokines and sarcoidosis Ringkowski Sabine 1 2 3 Thomas Paul S. 1 2 * Herbert Cristan 1 1Inflammation and Infection Research Centre, Faculty of Medicine, University of New South Wales Sydney, NSW, Australia 2Respiratory Medicine Department, Prince of Wales Hospital Sydney, NSW, Australia 3Faculty of Medicine, University of Heidelberg Heidelberg, Germany

Edited by: Stelios Loukides, University of Athens Medical School, Greece

Reviewed by: Jutaro Fukumoto, University of South Florida, USA; Effrosyni D. Manali, National and Kapodistrian University of Athens, Greece

*Correspondence: Paul S. Thomas, Respiratory Medicine Department, Prince of Wales Hospital, Level 2 Dickinson Building via High Street, Barker Street, Randwick, Sydney, NSW 2031, Australia e-mail: paul.thomas@unsw.edu.au

This article was submitted to Respiratory Pharmacology, a section of the journal Frontiers in Pharmacology.

 11 09 2014 27 10 2014 2014 5 233 04 08 2014 03 10 2014 Copyright © 2014 Ringkowski, Thomas and Herbert. 2014

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Sarcoidosis is a systemic granulomatous disease predominantly affecting the lungs. It is believed to be caused by exposure to pathogenic antigens in genetically susceptible individuals but the causative antigen has not been identified. The formation of non-caseating granulomas at sites of ongoing inflammation is the key feature of the disease. Other aspects of the pathogenesis are peripheral T-cell anergy and disease progression to fibrosis. Many T-cell-associated cytokines have been implicated in the immunopathogenesis of sarcoidosis, but it is becoming apparent that IL-12 cytokine family members including IL-12, IL-23, IL-27, and IL-35 are also involved. Although the members of this unique cytokine family are heterodimers of similar subunits, their biological functions are very diverse. Whilst IL-23 and IL-12 are pro-inflammatory regulators of Th1 and Th17 responses, IL-27 is bidirectional for inflammation and the most recent family member IL-35 is inhibitory. This review will discuss the current understanding of etiology and immunopathogenesis of sarcoidosis with a specific focus on the bidirectional impact of IL-12 family cytokines on the pathogenesis of sarcoidosis.

 sarcoidosis IL-12 IL-23 IL-27 IL-35 pathogenesis granuloma anergy INTRODUCTION

The term sarcoidosis was first used in 1899 to describe pathological features of skin lesions, but is currently used to describe a systemic granulomatous inflammatory disease predominantly affecting the lungs (Boeck, 1899; Müller-Quernheim et al., 2012). The non-caseating granulomas observed in affected tissues remain its key pathological feature (Heinle and Chang, 2014). More than 100 years of research have been unable to reveal the etiology and pathogenesis of the disease.

Current investigations into the pathogenesis include studies of gene polymorphisms and the role of possible infective and non-infective antigens (Adrianto et al., 2012; Negi et al., 2012; Dubaniewicz et al., 2013). Important questions that remain unexplained are how and why granulomas are formed and why approximately 20% of all patients develop pulmonary fibrosis whereas the majority experience remission (Iannuzzi and Fontana, 2011; Müller-Quernheim et al., 2012; Broos et al., 2013; Loke et al., 2013). Also yet to be explained is the observed anergy of peripheral T-cells in affected patients (Lee et al., 2011).

The IL-12 family of cytokines, (IL-12, IL-23, IL-27, and IL-35), have been implicated in other granulomatous inflammatory diseases such as tuberculosis and Crohn’s disease, and a role for some of these cytokines has also been proposed in sarcoidosis (Larousserie et al., 2004; Mroz et al., 2008; Judson et al., 2012). Thus the purpose of this review is to discuss the current understanding of the etiology and pathogenesis of sarcoidosis with a focus on a possible role for the IL-12 family cytokines.

 EPIDEMIOLOGY

The incidence and prevalence of sarcoidosis varies between different ethnic groups. Sarcoidosis is more common in females and peak incidence is between 30–50 years (Rybicki and Iannuzzi, 2007). African Americans and Northern Europeans have the highest incidence rate ranging between 15–80/100.000 (Rybicki and Iannuzzi, 2007). Interestingly more recent studies in different countries all reveal an increased prevalence and incidence compared to former reports, indicating that sarcoidosis might be more common than previously thought (Deubelbeiss et al., 2010; Nicholson et al., 2010; Erdal et al., 2012).

 ETIOLOGY

Sarcoidosis is believed to be caused by exposure to antigens and environmental agents in genetically susceptible individuals (Eishi, 2013).

The ACCESS study (A case control etiologic study of sarcoidosis) identified exposure to insecticides as well as mold, mildew, and musty odors as risk factors pointing towards a role of microbial bioaerosols in the pathogenesis of sarcoidosis (Newman et al., 2004). The same study confirmed a significantly higher risk for first and second degree relatives of affected patients to be diagnosed with sarcoidosis suggesting an involvement of genetic factors (Rybicki et al., 2001).

POTENTIAL ANTIGENS

Several observations support the idea of microbial antigens playing a role in the pathogenesis of sarcoidosis. Early studies found that tissue samples from sarcoid patients injected into animals caused granuloma formation (Iwai and Takahashi, 1976; Mitchell et al., 1976). However when similar samples are disinfected they do not cause granuloma formation, suggesting a cell-mediated or microbial origin (Ikonomopoulos et al., 2000, 2006). Similarly several case reports indicate that sarcoidosis might be transmittable via organ transplantations (Burke et al., 1990; Heyll et al., 1994; Padilla et al., 2002; Pukiat et al., 2011; Das et al., 2012). Likewise, there are reports of both successful antibiotic and antifungal treatment of sarcoidosis perhaps related to the potential sarcoid antigens, Mycobacterium tuberculosis, Propionibacterium acnes, and more recently, fungi (Terčelj et al., 2007, 2011a; Drake et al., 2013; Takemori et al., 2014).

As sarcoidosis is a granulomatous disease, M. tuberculosis has long been suspected to be involved, yet the bacterium has never been isolated from sarcoid tissue (Milman et al., 2004). Nonetheless newer methods of detection have revealed that M. tuberculosis antigens are present in sarcoid lesions (Gupta et al., 2007; Oswald-Richter et al., 2012). Peripheral blood mononuclear cells (PBMCs) as well as bronchoalveolar lavage fluid (BAL) cells show hypersensitivity when stimulated with those antigens, producing higher amounts of interferon gamma (IFNy) than healthy controls without Bacillus Calmette-Guerin vaccination (Oswald-Richter et al., 2009, 2012; Ahmadzai et al., 2012).

Similarly, P. acnes antigens cause hypersensitivity in only a subgroup of patients but the bacterium is detected in and isolated from sarcoid lymph nodes and tissue more frequently than in healthy controls (Furusawa et al., 2012; Negi et al., 2012).

Fungal exposure is another risk factor for sarcoidosis and higher levels of beta-glucan (a fungal cell wall component) have been found in BAL fluid of patients compared to controls suggesting a possible role for fungal antigens in sarcoidosis (Newman et al., 2004; Terčelj et al., 2011b, 2013).

Despite the evidence for involvement of both M. tuberculosis antigens and P. acnes as well as fungal exposure in the pathogenesis of sarcoidosis, these organisms only amount for a subgroup of patients leaving room for other theories that suggest a role for non-microbial antigen such as autoantigens, serum amyloid A, and human heat shock proteins (Salazar et al., 2000; Wahlstrom et al., 2007, 2009; Chen et al., 2010; Bargagli et al., 2011; Dubaniewicz, 2013; Zhang et al., 2013).

 GENE POLYMORPHISMS

Just as there is probably no single “sarcoid antigen,” there is no single “sarcoidosis gene.” Multiple gene polymorphisms associated with sarcoidosis have been identified in different regional subgroups but many of the results can not be reproduced in different cohorts (Spagnolo and Grunewald, 2013). Human leucocyte antigen (HLA) polymorphisms have received the most attention with the hypothesis that sarcoidosis might be an antigen driven disease. Whilst HLA-DRB1∗03 is associated with an increased risk for Löfgren’s syndrome, HLA-DRB1∗07, ∗11, ∗14, and ∗15 are related to chronic disease while HLA∗DRB∗01 and ∗13 seem to be protective (Grunewald et al., 2010; Sato et al., 2010; Wijnen et al., 2010; Grubic et al., 2011; Zhou et al., 2011; Wennerstrom et al., 2012). Only two non-HLA polymorphisms have been confirmed: annexin A11 being protective whereas a butyrophilin-like 2 polymorphism is associated with chronic disease (Spagnolo et al., 2007; Milman et al., 2011; Wijnen et al., 2011; Adrianto et al., 2012; Morais et al., 2012; Suzuki et al., 2012). More recently, genome-wide association studies and single polymorphism analyses have also suggested a role for toll-like receptors, the myeloid differentiation primary response gene (Judson et al., 2012), IL-23 receptor (IL-23R), TNF-α, IL-10, NOTCH4, and OS9 polymorphisms (Veltkamp et al., 2007; Vasakova et al., 2010; Kim et al., 2011; Adrianto et al., 2012; Daniil et al., 2013; Hofmann et al., 2013; Song et al., 2014; Wijnen et al., 2014). As yet, none of these findings have been shown to have external validity and their potential clinical significance and contribution to the pathogenesis remain to be determined. Thus the literature shows the concept of sarcoidosis being an antigen-driven immunoreaction in genetically susceptible individuals to be accurate in principle but lacking in specificity in all patient groups.

 PATHOGENESIS INITIATION, ACCUMULATION, AND EFFECTOR PHASE

Sarcoidosis is characterized by non-caseating granulomas that typically consist of a core of Th1 cells and activated macrophages surrounded by B-cells, fibroblasts and CD8 lymphocytes as well as Th17 cells, and Treg cells (Miyara et al., 2006; Iannuzzi and Fontana, 2011; Ten Berge et al., 2012). Granuloma formation can be explained in four stages: initiation, accumulation, effector phase, resolution/development of fibrosis. It has traditionally been explained by antigen-driven Th1 responses and interactions between antigen presenting cells (APC) and Th1 cells but recent advances have implicated Th17 in the process of granuloma formation as well (Figure 1; Co et al., 2004; Chen and Moller, 2011; Iannuzzi and Fontana, 2011; Müller-Quernheim et al., 2012; Broos et al., 2013).

Granuloma formation – Th1/Th17 hypothesis. Initiation: alveolar macrophages (AM) and dendritic cells (DC) are activated by a putative antigen. DC migrates to lymph nodes and initiates Th1/Th17 cell amplification. Chemokines produced by alveolar macrophages attract Th1/17, Treg, B-cells as well as CD8+ cells and fibroblast and initiate granuloma formation (effector phase). Both DC and macrophages produce cytokines favoring Th1 and Th17 cells in sarcoidosis. Figure adopted from Broos et al. (2013).

Th1 cell accumulation in the lungs is characteristic of sarcoidosis and these cells spontaneously produce increased amounts of IL-2 and IFNγ in the BAL fluid (Robinson et al., 1985; Moseley et al., 1986; Prasse et al., 2000). The development of these Th1 cells depends on IL-12 and IL-18, both of which are elevated in the BAL fluid of sarcoidosis patients supporting a Th1-based hypothesis of granuloma formation (Stoll et al., 1998; Yoshimoto et al., 1998; Shigehara et al., 2001; Mroz et al., 2008).

Increased numbers of Th17 cells in BAL, blood and granulomatous tissue of sarcoidosis patients suggest a contribution of these cells in the pathogenesis of sarcoidosis (Facco et al., 2011; Ten Berge et al., 2012; Richmond et al., 2013). Th17 cells are a subset of pro-inflammatory CD4+ cells that are associated with autoimmunity and antimicrobial defense (Bedoya et al., 2013). They develop from naïve CD4+ T-cells in the presence of TGFβ, IL-1β, IL-6, and IL-23 (Acosta-Rodriguez et al., 2007; Wilson et al., 2007; Manel et al., 2008; Volpe et al., 2008). In patients with sarcoidosis IL-1β, IL-6, and TGFβ are elevated in the BAL fluid compared to healthy controls and IL-23 has been detected in granulomas creating a Th17 supportive microenvironment (Zissel et al., 1996; Idali et al., 2006; Judson et al., 2012; Urbankowski et al., 2012). A few studies have analyzed the role of the Th17 effector cytokines IL-17A/F, IL-21, and IL-22 in sarcoidosis, but the results are contradictory. One group demonstrated that sarcoid Th17 cells produce more IL-17A compared to healthy controls, whereas others demonstrated that IL-17 was down-regulated after stimulation with P. acnes (Furusawa et al., 2012; Richmond et al., 2013). In skin lesions of sarcoidosis patients, IL-21 has been found to be elevated, whereas IL-17 and IL-22 were not dysregulated (Judson et al., 2012). Thus there is some evidence for a role of Th17 cells in granuloma formation but more studies are needed to define the role of Th17 effector cytokines.

 RESOLUTION VERSUS FIBROSIS

The factors determining the clinical course of sarcoidosis, either granuloma resolution or progression to fibrosis, remain unclear (Patterson et al., 2012). On a cellular level remission is believed to occur through antigen clearance through a strong Th1 response and recovery of regulatory T-cells (Treg; Müller-Quernheim et al., 2012; Oswald-Richter et al., 2013). There is evidence supporting the theory that fibrosis is caused by a switch from Th1 responses towards Th2 (Iannuzzi et al., 2007; Müller-Quernheim et al., 2012). In line with this hypothesis, the concentration of the Th2 cytokine IL-5 is lower in those without fibrosis compared to those with fibrotic disease (Patterson et al., 2013). Further support for a switch to Th2 responses is provided by several studies that identified a Th2 driven immunosuppressive polarization of alveolar macrophages (AM) in fibrotic patients although these findings remain controversial (Prasse et al., 2006; Wikén et al., 2010; Prokop et al., 2011). Thus there is some evidence suggesting a contribution of Th2 responses to the development of fibrosis but further studies are required to confirm this theory. It may also be worth exploring a potential role of other immunosuppressive cytokines such as IL-27 and IL-35.

 IMMUNE PARADOX AND PERIPHERAL ANERGY

T-cell anergy is a term to describe hypo-responsiveness or incomplete activation of T-cells after exposure to common recall antigens, thought to be associated with a lack of adequate co-stimulation or overexposure to co-inhibitory signals (Crespo et al., 2013). In sarcoidosis, anergy is used to describe a lack of reaction to skin antigen tests (delayed type hypersensitivity) and ex vivo exposure to common recall antigens in peripheral blood (Mathew et al., 2008; Ahmadzai et al., 2012). This contrasts with the extensive local inflammation at sites of active disease and thus the phenomenon is also often referred to as an immune paradox (Miyara et al., 2006). Mechanisms of the observed sarcoid anergy are poorly understood and several theories have been proposed including compartmentalization of immune competent cells to the lung and, more recently, Treg, dendritic cells (DC), and T effector (Teff) cell dysfunction (Miyara et al., 2006; Mathew et al., 2008; Lee et al., 2011).

In fact it was initially hypothesized that the sarcoid peripheral anergy could be due to increased numbers of Treg cells that suppress proliferation of Teff cells (Miyara et al., 2006). Further studies confirmed that Treg cells are amplified in blood, BAL, and lymph node tissue of sarcoidosis patients, but these same studies indicate that these cells may in fact be impaired in their repressor function and might even contribute to pro-inflammatory granuloma formation (Taflin et al., 2009; Rappl et al., 2011; Oswald-Richter et al., 2013). Interestingly, disease resolution is associated with reversal of Th1 and Treg dysfunction (Oswald-Richter et al., 2013). Thus the original idea of Tregs contributing to peripheral anergy does not fully explain the phenomenon but nonetheless the cells seem to be dysregulated in sarcoidosis. Interestingly, peripheral blood and BAL sarcoid T-cells show selective hypersensitivity to possible sarcoid antigens while not only peripheral blood but also sarcoid BAL cells are hypo-responsive to common recall antigens (Ahmadzai et al., 2012; Oswald-Richter et al., 2013). It may be that instead of peripheral anergy, sarcoidosis is rather characterized by selective hypersensitivity to disease related antigens and hyporesponsiveness to common recall antigens. Further studies are required to compare the selective hypersensitivity and anergy in cells from BAL and peripheral blood. Likewise a role for immunosuppressive cytokines in the context of peripheral anergy in sarcoidosis should also be considered.

 IL-12 FAMILY CYTOKINES

Whilst the pathogenesis of granuloma formation in sarcoidosis may be at odds with observed anergy in peripheral immune cells, one possible unifying factor may be the IL-12 family of cytokines. They are a unique group of heterodimeric cytokines composed of one of the three alpha subunits p19, p35, or p28 and one of the two beta subunits p40 or Epstein-Barr virus induced gene 3 (EBI3; Figure 2; Vignali and Kuchroo, 2012). p40 is the shared beta-subunit of IL-12 and IL-23, whereas IL-27 and IL-35 consist of the beta unit EBI3. The alpha subunit p19 is specific for IL-23 as is p28 for IL-27, whereas p35 is shared by IL-12 and IL-35. Similarly they bind to heterodimeric receptors and share five receptor subunits. Despite their common structures the biological function of the members of this family is very diverse (Figure 2). Whilst IL-12 and IL-23 are pro-inflammatory, IL-27 is bi-directional in terms of being both pro- and anti-inflammatory while IL-35 is strongly immunosuppressive (Vignali and Kuchroo, 2012).

IL-12 family members. IL-12 family members are heterodimers sharing three α-chains (p35, p19, p28) and two β-chains (p40, EBI3). Similarly the receptors also consist of heterodimers. Signaling is mediated by the Jak-STAT family and affects different T-eff cell subsets. IL-23 and IL-12 act mainly pro-inflammatory through the activation of Th17 and Th1 cells, IL-27 seems to act in a pro-inflammatory manner on naïve T-cells and as an anti-inflammatory mediator on T-eff cells. IL-35 is immunosuppressive, inducing iTr35 cells. Green arrows indicate pro-inflammatory effects, red arrows represent anti-inflammatory properties.

 IL-12

A role for IL-12 in sarcoid granuloma formation is well established (Figure 1; Iannuzzi and Fontana, 2011; Broos et al., 2013). Multiple studies confirm that IL-12p40 is elevated in blood, BAL, and granulomatous tissue from sarcoidosis patients and PBMC as well as BAL cells stimulated with sarcoid associated antigens produce higher amounts of IL-12 p40 in patients compared to healthy controls (Table 1). The corresponding IL-12 receptor chain IL-12Rβ1 is equally over-expressed in peripheral blood and BAL of sarcoidosis patients (Rogge et al., 1999; Taha et al., 1999; Judson et al., 2012). IL-12 is known to increase IFNγ production and this holds true in sarcoid patients compared to controls (Shigehara et al., 2001). Recent studies suggest that Th17 cells may also produce IFNγ in the presence of IL-12 (Annunziato et al., 2007; Boniface et al., 2010). IFNγ has been shown to play a pivotal role in lung granuloma formation in murine models of tuberculosis (Cooper et al., 1997). It is thus likely that IL-12 (through promoting IFNγ) is of similar importance in sarcoidosis granuloma formation.

Studies on IL-12 and IL-12 receptors in sarcoidosis.

Peripheral blood:
Method Result Reference
ELISA IL-12 p40 increased, IL-12p70 not detected (ELISA). Shigehara et al. (2003),Hata et al. (2007)
Antibody detection IL-12Rβ2 not detected. Rogge et al. (1999)
mRNA, rtPCR IL-12Rβ1 is elevated compared to healthy controls, but IL-12Rβ2 is not. Judson et al. (2012)
Granuloma lesions:
Affected organ Method Result Reference
Skin mRNA, rtPCR IL-12p40, IL-12Rβ1 and IL-12Rβ2 are elevated compared to controls. Judson et al. (2012)
Myocardium IL12 ELISA and mRNA IL-12 is elevated (antibody not specified). IL-12p40 and IL-12p35 mRNA are present but only IL12p40 significantly increased compared to dilated cardiomyopathy controls. Terasaki et al. (2008)
Lung Immunohistochemistry IL12p70 is overexpressed by epithelioid cells and macrophages as well as giant cells. Shigehara et al. (2001)
Lymph node mRNA, rtPCR IL-12p40 mRNA and IL-12Rβ2 mRNA is elevated, but not IL12p35 or IL-12Rβ1 Hata et al. (2007)
Lung and lymph node Immunohistochemistry IL-12p40 is expressed by epithelioid cells and macrophages. Shigehara et al. (2003)
Lymph node mRNA IL-12p40 is significantly increased compared to controls but not IL-12p35. Bergeron et al. (1997)
BAL:
Method of detection Result Reference
mRNA, ELISA IL-12p40 mRNA and protein levels are significantly increased compared to healthy controls. BAL macrophages express higher levels of IL-12p70 both unstimulated and stimulated. Moller et al. (1996)
ELISA IL-12p40 is elevated compared to healthy controls, but not IL-12p70. Shigehara et al. (2001), Barbarin et al. (2003)
Cytometric bead array IL12p70 levels are significantly higher in patients compared to healthy controls. Idali et al. (2006)
ELISA (not specified) IL-12 (not specified) is elevated compared to healthy controls. Kim et al. (2000), Meloni et al. (2004), Antoniou et al. (2006), Mroz et al. (2008)
FISH mRNA detection IL-12p40 significantly elevated in patients with active sarcoidosis but not inactive sarcoidosis. Minshall et al. (1997)
mRNA IL-12Rβ1 and IL-12Rβ2 levels are elevated in sarcoidosis patients. Taha et al. (1999)
Antibody detection BAL cells of sarcoidosis patients express IL-12Rβ2. Rogge et al. (1999)
Stimulation assays with sarcoid antigens
Stimulus Cells Result Reference
P. acnes PBMC IL-12p40 mRNA levels are significantly elevated in sarcoidosis patients compared to healthy controls. Furusawa et al. (2012)
β-glucan/LPS PBMC Spontaneous and post-stimulation IL-12 protein levels are higher in patients compared to controls (IL 12 ELISA not further specified). Rastogi et al. (2011)
NOD1/TLR4 ligands BALF IL12/23 p40 protein and mRNA levels are increased compared to healthy controls. Rastogi et al. (2011)
Multiple studies confirm IL-12p40 and IL-12Rβ1 up-regulation in peripheral blood, BAL, and granulomatous tissue, while the corresponding IL-12p35 is not dysregulated and IL-12p70 (the functional IL-12 protein) in most studies not detectable. IL-23

IL-23 promotes the expansion and survival of Th17 cells, which have recently been linked to sarcoid granuloma formation (Figure 1; Broos et al., 2013). Gene analyses have revealed IL-23 receptor polymorphisms in sarcoidosis patients (Fischer et al., 2011; Kim et al., 2011). Furthermore IL-23 receptor mRNA is elevated in the granulomatous skin lesions of sarcoidosis patients and the same study also observed a trend for up-regulation of IL-23 p19 in two thirds of sarcoid skin lesions, yet not in peripheral blood (Judson et al., 2012). Upon ex vivo stimulation with toll-like receptor 9 agonists, PBMCs of sarcoidosis patients produce less IL-23 compared to healthy controls suggesting that IL-23 might play a role in the formation of granulomas but not in peripheral blood (Veltkamp et al., 2010). Given the fact that IL-23 mostly acts as a pro-inflammatory cytokine through the promotion of Th17 development, these findings underline a possible role of Th17 cells in sarcoidosis. There is evidence that the Th17 cytokine IL-17A is required in granuloma formation following infection with mycobacteria (Fitzgerald et al., 2013). Since there are to date no murine models of sarcoidosis it is difficult to verify whether Th17/IL-17A contribution is essential in sarcoidosis as well. Yet IL-23 might promote IL-17A production by Th17 cells and thus contribute to pulmonary granuloma formation.

 IL-27

Somewhat uniquely, IL-27 has been shown to have both pro- and anti-inflammatory effects (Table 2). Early studies focused on pro-inflammatory effects as IL-27 was shown to initiate clonal expansion of naïve T-cells and enhance INFγ production together with IL-12 (Pflanz et al., 2002). It was also found to induce Th1 differentiation and showed pro-inflammatory effects on monocytes (Owaki et al., 2005, 2006; Kalliolias and Ivashkiv, 2008). In contrast to those findings, IL-27 receptor deficient mice that are infected with Toxoplasma gondii can still develop an immune response but are then unable to down-regulate that response, which ultimately proves to be fatal (Villarino et al., 2003). This suggests a pivotal role of IL-27 in immune modulation and one mechanism by which this is effected may be IL-10 induction in Th1, Th2, Th17, and Treg cells. These effects seem to be mediated via both the STAT1 and STAT3 proteins (Stumhofer et al., 2007). IL-27 also promotes IL-10 – producing regulatory type 1 T-cells (Treg1) and can directly suppress Th17 cells (Apetoh et al., 2010; Sweeney et al., 2011; Fitzgerald et al., 2013). These results suggest a bidirectional function of IL-27, and while it seems to induce a pro-inflammatory response in naïve cells, the opposite is the case in activated cells (Kalliolias and Ivashkiv, 2008; Fitzgerald et al., 2013).

Recent findings on pro- and anti-inflammatory effects of recombinant IL-27 on human cells in ex vivo studies.

Stimulated cells Finding Reference
Pro-inflammatory
Human monocytes Pro-inflammatory response in resting human monocytes. TLR responses are enhanced in the presence of IL-27. Kalliolias and Ivashkiv (2008)
Human APC Induction of pro-inflammatory CXCL10 and enhancement of TLR responses. Inhibition of LPS and CD40L mediated IL-10 production. Zeitvogel et al. (2012)
Aplastic anaemia patients: human bone marrow mononuclear cells. IFNγ and TNFα induction in bone marrow mononuclear cells. Li et al. (2011)
Anti-inflammatory
Human PBMC IL-27 upregulates IL-10 production in activated PMBCs. Fitzgerald et al. (2013)
Human PBMC Suppression of Th17 cell development and IL-17 production in the presence of IL-23. Fitzgerald et al. (2013)
Human DC IL-23 enhancement after stimulation with zymosan/IFNβ is suppressed by IL-27. Sweeney et al. (2011)
Murine studies on IL-27 suggest a bidirectional function of the cytokine in terms of pro- and anti-inflammatory immune modulation. Recent ex vivo studies on human cells indicate that IL-27 might enhance inflammation in resting cells but inhibit immune responses in activated cells.

IL-27 and STAT3 were not dysregulated in sarcoid skin granulomas whereas STAT1 and STAT3 mRNA levels were elevated in the peripheral blood of sarcoidosis patients compared to healthy controls, but another group detected co-expression of the IL-27 subunits EBI3 and p28 (Figure 2) in epithelioid and multinucleate granuloma cells in sarcoid lymph nodes, suggesting a role of IL-27 in granuloma formation or resolution (Larousserie et al., 2004; Judson et al., 2012). Interestingly IL-27R-/- mice produce less IFNγ at sites of granuloma formation in tuberculosis mice models suggesting that IL-27 might similarly contribute to early stages of granuloma formation in sarcoidosis (Pearl et al., 2004). At the same time IL-27 inhibits the production of TNF-α and IL-12 in activated peritoneal macrophages, suggesting an IL-27-mediated regulation of inflammation directed by macrophages in a murine model of tuberculosis (Li et al., 2012). The cytokine has recently been shown to be chemotactic for human DC and to impair HLA Class I antigen presentation in those cells (Morandi et al., 2014) and as the latter is believed to cause granuloma formation, IL-27 might thus also alter antigen presentation in sarcoidosis. IL-27 is a promising candidate for immune regulation in sarcoidosis but further studies are required to confirm IL-27 dysregulation in sarcoid tissue, analyse IL-27 expression in BALF and blood, and determine the effects of the cytokine in sarcoidosis and clarify whether it promotes inflammation and granuloma formation or contributes to disease clearance through its anti-inflammatory properties.

 IL-35

IL-35 is the most recently identified member of the cytokine family. It seems to be mainly expressed upon stimulation and there is some evidence for human Treg cells as well as DC to be a source of this cytokine (Seyerl et al., 2010; Li et al., 2012; Guttek and Reinhold, 2013). IL-35 is so far believed to be strictly immunosuppressive, mediating regulatory B- and T-cell function and increasing IL-35 – induced regulatory T-cells which express IL-35 (iTr35), as well as inhibiting effector T-cell proliferation and Th17 development and function (Niedbala et al., 2007; Collison et al., 2010, 2012; Olson et al., 2013; Ye et al., 2013; Wang et al., 2014). There are only a few studies on the role of IL-35 in human diseases and disease models to date and unlike the other IL-12 family members there are currently no studies on IL-35 in sarcoidosis. In murine models of airway inflammation, IL-35 suppressed airway hyperresponsiveness via IL-17 suppression and is elevated in BAL upon treatment with erythromycin suggesting a role for IL-35 in ameliorating airway inflammation (Bai et al., 2012; Whitehead et al., 2012). Similarly transfer of iTr35 as well as Treg cells can cure experimental inflammatory bowel disease in mice, but not if those Treg cells lack either p35 or EBI3 (Collison et al., 2007, 2010). Sarcoidosis often presents as airway inflammation and non-caseating granulomas are a feature shared with Crohn’s disease, an inflammatory bowel disease. Since Treg cell dysfunction and Th17 cells have also recently been linked to the pathogenesis of sarcoidosis IL-35 is an interesting target for further research in sarcoidosis that might contribute to disease clearance or the observed peripheral anergy.

 CONCLUSION AND PERSPECTIVES

The etiology and pathogenesis of sarcoidosis remain enigmatic. Current concepts assume that the disease is caused by exposure to disease related antigens in genetically susceptible individuals. Although sarcoidosis was initially believed to be a Th1/IL-12/IFNγ mediated disease, more recent advances have also revealed a contribution of pro-inflammatory IL-23 and Th17 cells in granuloma formation. But little is known about IL-12 family members and their possible role in fibrosis development or peripheral anergy. Whilst both IL-12 and IL-23 seem to be crucial pro-inflammatory players in granuloma formation, the only randomized controlled trial to date does not show efficacy of IL-12 and IL-23 blockade with ustekinumab in sarcoidosis (Judson et al., 2014). Given the fact that IL-12 enhances IFNγ which then promotes granuloma formation the monoclonal IFNγ antibody fontolizumab is another promising drug in the treatment of sarcoidosis showing some effects in phase 2 clinical trials in Crohn’s disease (Hommes et al., 2006). The bidirectional IL-27 has also been detected in granulomas but further studies are required in order to determine whether it enhances inflammation or downregulates the excessive immune response at sites of inflammation.

However, since both IL-35 and IL-27 also have immunosuppressive properties further studies on a potential contribution to disease remission of these immunosuppressive cytokines could shed more light on the pathogenesis of sarcoid-related fibrosis and anergy. A clearer immunosuppressive function may indicate a role for stimulation of these cytokine and their receptors in the treatment of sarcoidosis and they could also be potential diagnostic markers for the disease.

 Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

 REFERENCES Acosta-Rodriguez E. V. Napolitani G. Lanzavecchia A. Sallusto F. (2007). Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat. Immunol. 8 942–949. 10.1038/ni1496 Adrianto I. Lin C. P. Hale J. J. Levin A. M. Datta I. Parker R. (2012). Genome-wide association study of African and European Americans implicates multiple shared and ethnic specific loci in sarcoidosis susceptibility. PLoS ONE 7:e43907. 10.1371/journal.pone.0043907 Ahmadzai H. Cameron B Chui J. J. Lloyd A. Wakefield D. Thomas P. S. (2012). Peripheral blood responses to specific antigens and CD28 in sarcoidosis. Respir. Med. 106 701–709. 10.1016/j.rmed.2012.01.012 Annunziato F. Cosmi L. Santarlasci V. Maggi L. Liotta F. Mazzinghi B. (2007). Phenotypic and functional features of human Th17 cells. J. Exp. Med. 204 1849–1861. 10.1084/jem.20070663 Antoniou K. M. Tzouvelekis A. Alexandrakis M. G. Tsiligianni I. Tzanakis N. Sfiridaki K. (2006). Upregulation of Th1 cytokine profile (IL-12, IL-18) in bronchoalveolar lavage fluid in patients with pulmonary sarcoidosis. J. Interferon Cytokine Res. 26 400–405. 10.1089/jir.2006.26.400 Apetoh L. Quintana F. J. Pot C. Joller N. Xiao S. Kumar D. (2010). The aryl hydrocarbon receptor interacts with c-Maf to promote the differentiation of type 1 regulatory T cells induced by IL-27. Nat. Immunol. 11 854–861. 10.1038/ni.1912 Bai J. Qiu S. L. Zhong X. N. Huang Q. P. He Z. Y. Zhang J. Q. (2012). Erythromycin enhances CD4+Foxp3+ regulatory T-cell responses in a rat model of smoke-induced lung inflammation. Mediators Inflamm. 2012 410232. 10.1155/2012/410232 Barbarin V. Petrek M. Kolek V. Van Snick J. Huaux F. Lison D. (2003). Characterization of p40 and IL-10 in the BALF of patients with pulmonary sarcoidosis. J. Interferon Cytokine Res. 23 449–456. 10.1089/107999003322277865 Bargagli E. Magi B. Olivieri C. Bianchi N. Landi C. Rottoli P. (2011). Analysis of serum amyloid a in sarcoidosis patients. Respir. Med. 105 775–780. 10.1016/j.rmed.2010.12.010 Bedoya S. K. Lam B. Lau K. Larkin J. III (2013). Th17 cells in immunity and autoimmunity. Clin. Dev. Immunol. 2013 986789. 10.1155/2013/986789 Bergeron A. Bonay M. Kambouchner M. Lecossier D. Riquet M. Soler P. (1997). Cytokine patterns in tuberculous and sarcoid granulomas: correlations with histopathologic features of the granulomatous response. J. Immunol. 159 3034–3043. Boeck C. (1899). Multipelt Benignt Hud-Sarkoid. Kristiania (Oslo): Steen’ske bogtrykkeri. Boniface K. Blumenschein W. M. Brovont-Porth K. McGeachy M. J. Basham B. Desai B. (2010). Human Th17 cells comprise heterogeneous subsets including IFN-γ–producing cells with distinct properties from the Th1 lineage. J. Immunol. 185 679–687. 10.4049/jimmunol.1000366 Broos C. E. van Nimwegen M. Hoogsteden H. C. Hendriks R. W. Kool M. van den Blink B. (2013). Granuloma formation in pulmonary sarcoidosis. Front. Immunol. 4:437. 10.3389/fimmu.2013.00437 Burke W. M. Keogh A. Maloney P. J. Delprado W. Bryant D. H. Spratt P. (1990). Transmission of sarcoidosis via cardiac transplantation. Lancet 336 1579. 10.1016/0140-6736(90)93354-R Chen E. S. Moller D. R. (2011). Sarcoidosis–scientific progress and clinical challenges. Nat. Rev. Rheumatol. 7 457–467. 10.1038/nrrheum.2011.93 Chen E. S. Song Z. Willett M. H. Heine S. Yung R. C. Liu M. C. (2010). Serum amyloid a regulates granulomatous inflammation in sarcoidosis through Toll-like receptor-2. Am. Respir. Crit. Care Med. 181 360–371. 10.1164/rccm.200905-0696OC Co D. O. Hogan L. H. Il-Kim S. Sandor M. (2004). T cell contributions to the different phases of granuloma formation. Immunol. Lett. 92 135–142. 10.1016/j.imlet.2003.11.023 Collison L. W. Chaturvedi V. Henderson A. L. Giacomin P. R. Guy C. Bankoti J. (2010). IL-35-mediated induction of a potent regulatory T cell population. Nat. Immunol. 11 1093–1101. 10.1038/ni.1952 Collison L. W. Delgoffe G. M. Guy C. S. Vignali K. M. Chaturvedi V. Fairweather D. (2012). The composition and signaling of the IL-35 receptor are unconventional. Nat. Immunol. 13 290–299. 10.1038/ni.2227 Collison L. W. Workman C. J. Kuo T. T. Boyd K. Wang Y. Vignali K. M. (2007). The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 450 566–569. 10.1038/nature06306 Cooper A. M. Magram J. Ferrante J. Orme I. M. (1997). Interleukin 12 (IL-12) is crucial to the development of protective immunity in mice intravenously infected with Mycobacterium tuberculosis. J. Exp. Med. 186 39–45. 10.1084/jem.186.1.39 Crespo J. Sun H. Welling T. H. Tian Z. Zou W. (2013). T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment. Curr. Opin. Immunol. 25 214–221. 10.1016/j.coi.2012.12.003 Daniil Z. Mollaki V. Malli F. Koutsokera A. Antoniou K. Rodopoulou P. (2013). Polymorphisms and haplotypes in MyD88 are associated with the development of sarcoidosis: a candidate-gene association study. Mol. Biol. Rep. 40 4281–4286. 10.1007/s11033-013-2513-7 Das B. B. Shoemaker L. Kim E. Mascio C. E. Austin E. H. (2012). Severe calcification of the aorta (porcelain aorta) associated with sarcoidosis in a pediatric heart transplant recipient. Pediatric Transplant. 16 E162–E166. 10.1111/j.1399-3046.2011.01557.x Deubelbeiss U. Gemperli A. Schindler C. Baty F. Brutsche M. H. (2010). Prevalence of sarcoidosis in Switzerland is associated with environmental factors. Eur. Respir. J. 35 1088–1097. 10.1183/09031936.00197808 Drake W. P. Oswald-Richter K. Richmond B. W. Isom J. Burke V. E. Algood H. (2013). Oral antimycobacterial therapy in chronic cutaneous sarcoidosis: a randomized, single-masked, placebo-controlled study. J. Am. Acad. Dermatol. 149 1040–1049. 10.1001/jamadermatol.2013.4646 Dubaniewicz A. (2013). Microbial and human heat shock proteins as ‘danger signals’ in sarcoidosis. Hum. Immunol. 74 1550–1558. 10.1016/j.humimm.2013.08.275 Dubaniewicz A. Holownia A. Kalinowski L. Wybieralska M. Dobrucki I. T. Singh M. (2013). Is mycobacterial heat shock protein 16kDa, a marker of the dormant stage of Mycobacterium tuberculosis, a sarcoid antigen? Hum. Immunol. 74 45–51. 10.1016/j.humimm.2012.10.007 Eishi Y. (2013). Etiologic link between sarcoidosis and Propionibacterium acnes. Respir. Investig. 51 56–68. 10.1016/j.resinv.2013.01.001 Erdal B. S. Clymer B. D. Yildiz V. O. Julian M. W. Crouser E. D. (2012). Unexpectedly high prevalence of sarcoidosis in a representative US Metropolitan population. Respir. Med. 106 893–899. 10.1016/j.rmed.2012.02.007 Facco M. Cabrelle A. Teramo A. Olivieri V. Gnoato M. Teolato S. (2011). Sarcoidosis is a Th1/Th17 multisystem disorder. Thorax 66 144–150. 10.1136/thx.2010.140319 Fischer A. Nothnagel M. Franke A. Jacobs G. Saadati H. R. Gaede K. I. (2011). Association of inflammatory bowel disease risk loci with sarcoidosis, and its acute and chronic subphenotypes. Eur. Respir. J. 37 610–616. 10.1183/09031936.00049410 Fitzgerald D. C. Fonseca-Kelly Z. Cullimore M. L. Safabakhsh P. Saris C. J. Zhang G. X. (2013). Independent and interdependent immunoregulatory effects of IL-27, IFN-β, and IL-10 in the suppression of human Th17 cells and murine experimental autoimmune encephalomyelitis. J. Immunol. 190 3225–3234. 10.4049/jimmunol.1200141 Furusawa H. Suzuki Y. Miyazaki Y. Inase N. Eishi Y. (2012). Th1 and Th17 immune responses to viable Propionibacterium acnes in patients with sarcoidosis. Respir. Investig. 50 104–109. 10.1016/j.resinv.2012.07.001 Grubic Z. Peros-Golubicic T. Stingl K. Zunec R. (2011). The investigation of HLA microsatellites influence in predisposition to sarcoidosis among Croatians. Sarcoidosis Vasc. Diffuse Lung Dis. 28 18–26. Grunewald J. Brynedal B. Darlington P. Nisell M. Cederlund K. Hillert J. (2010). Different HLA-DRB1 allele distributions in distinct clinical subgroups of sarcoidosis patients. Respir. Res. 11 25. 10.1186/1465-9921-11-25 Gupta D. Agarwal R. Aggarwal A. N. Jindal S. K. (2007). Molecular evidence for the role of mycobacteria in sarcoidosis: a meta-analysis. Eur. Respir. J. 30 508–516. 10.1183/09031936.00002607 Guttek K. Reinhold D. (2013). Stimulated human peripheral T cells produce high amounts of IL-35 protein in a proliferation-dependent manner. Cytokine 64 46–50. 10.1016/j.cyto.2013.04.037 Hata M. Sugisaki K. Miyazaki E. Kumamoto T. Tsuda T. (2007). Circulating IL-12 p40 is increased in the patients with sarcoidosis, correlation with clinical markers. Int. Med. 46 1387–1393. 10.2169/internalmedicine.46.6278 Heinle R. Chang C. (2014). Diagnostic Criteria for Sarcoidosis. Autoimmun. Rev. 13 383–387. 10.1016/j.autrev.2014.01.035 Heyll A. Meckenstock G. Aul C. Sohngen D. Borchard F. Hadding U. (1994). Possible transmission of sarcoidosis via allogeneic bone marrow transplantation. Bone Marrow Transplant. 14 161–164. Hofmann S. Fischer A. Nothnagel M. Jacobs G. Schmid B. Wittig M. (2013). Genome-wide association analysis reveals 12q13. 3–q14. 1 as new risk locus for sarcoidosis. Eur. Respir. J. 41 888–900. 10.1183/09031936.00033812 Hommes D. W. Mikhajlova T. L. Stoinov S. Štimac D. Vucelic B. Lonovics J. (2006). Fontolizumab, a humanised anti-interferon γ antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn’s disease. Gut 55 1131–1137. 10.1136/gut.2005.079392 Iannuzzi M. C. Fontana J. R. (2011). Sarcoidosis: clinical presentation, immunopathogenesis, and therapeutics. J. Am. Med. Assoc. 305 391–399. 10.1001/jama.2011.10 Iannuzzi M. C. Rybicki B. A. Teirstein A. S. (2007). Sarcoidosis. N. Engl. J. Med. 357 2153–2165. 10.1056/NEJMra071714 Idali F. Wiken M. Wahlström J. Mellstedt H. Eklund A. Rabbani H. (2006). Reduced Th1 response in the lungs of HLA-DRB1* 0301 patients with pulmonary sarcoidosis. Eur. Respir. J. 27 451–9. 10.1183/09031936.06.00067105 Ikonomopoulos J. Gazouli M. Dontas I. Sechi L. Lukas J. C. Balaskas C. (2006). The infectivity of sarcoid clinical material and its bacterial content inoculated in CBA mice. In Vivo 20 807–813. Ikonomopoulos J. A. Gorgoulis V. G. Kastrinakis N. G. Galanos A. A. Karameris A. Kittas C. (2000). Experimental inoculation of laboratory animals with samples collected from sarcoidal patients and molecular diagnostic evaluation of the results. In Vivo 14 761–765. Iwai K. Takahashi S. (1976). Transmissibility of sarcoid-specific granulomas in the footpads of mice. Ann. N. Y. Acad. Sci. 278 249–259. 10.1111/j.1749-6632.1976.tb47036.x Judson M. A. Baughman R. P. Costabel U. Drent M. Gibson K. F. Raghu G. (2014). Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis. Eur. Respir. J. 10.1183/09031936.00000914 [Epub ahead of print]. Judson M. A. Marchell R. M. Mascelli M. Piantone A. Barnathan E. S. Petty K. J. (2012). Molecular profiling and gene expression analysis in cutaneous sarcoidosis: the role of interleukin-12, interleukin-23, and the T-helper 17 pathway. J. Am. Acad. Dermatol. 66 901–910. 10.1016/j.jaad.2011.06.017 Kalliolias G. D. Ivashkiv L. B. (2008). IL-27 activates human monocytes via STAT1 and suppresses IL-10 production but the inflammatory functions of IL-27 are abrogated by TLRs and p38. J. Immunol. 180 6325–6333. 10.4049/jimmunol.180.9.6325 Kim D. S. Jeon Y. G. Shim T. S. Lim C. M. Lee S. D. Koh Y. (2000). The value of interleukin-12 as an activity marker of pulmonary sarcoidosis. Sarcoidosis Vasc. Diffuse Lung Dis. 17 271–276. Kim H. S. Choi D. Lim L. L. Allada G. Smith J. R. Austin C. R. (2011). Association of interleukin 23 receptor gene with sarcoidosis. Dis. Mark. 31 17–24. 10.3233/DMA-2011-0796 Larousserie F. Pflanz S. Coulomb-L’Herminé A. Brousse N. Kastelein R. Devergne O. (2004). Expression of IL-27 in human Th1-associated granulomatous diseases. J. Pathol. 202 164–171. 10.1002/path.1508 Lee N. S. Barber L. Kanchwala A. Childs C. J. Kataria Y. P. Judson M. A. (2011). Low levels of NF-κB/p65 mark anergic CD4+ T cells and correlate with disease severity in sarcoidosis. Clin. Vaccine Immunol. 18 223–234. 10.1128/CVI.00469-10 Li J. Zhao Q. Xing W. Feng J. Wu H. Li H. (2011). Interleukin-27 enhances the production of tumour necrosis factor-alpha and interferon-gamma by bone marrow T lymphocytes in aplastic anaemia. Br. J. Haematol. 153 764–772. 10.1111/j.1365-2141.2010.08431.x Li X. Mai J. Virtue A. Yin Y. Gong R. Sha X. (2012). IL-35 is a novel responsive anti-inflammatory cytokine—a new system of categorizing anti-inflammatory cytokines. PLoS ONE 7:e33628. 10.1371/journal.pone.0033628 Loke W. S. J. Herbert C. Thomas P. S. (2013). Sarcoidosis: immunopathogenesis and immunological markers. Int. J. Chronic Dis. 2013 13. 10.1111/j.1440-1746.2011.06940.x Manel N. Unutmaz D. Littman D. R. (2008). The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat. Nat. Immunol. 9 641–649. 10.1038/ni.1610 Mathew S. Bauer K. L. Fischoeder A. Bhardwaj N. Oliver S. J. (2008). The anergic state in sarcoidosis is associated with diminished dendritic cell function. J. Immunol. 181 746–755. 10.4049/jimmunol.181.1.746 Meloni F. Caporali R. Marone Bianco A. Paschetto E. Morosini M. Fietta A. M. (2004). BAL cytokine profile in different interstitial lung diseases: a focus on systemic sclerosis. Sarcoidosis Vasc. Diffuse Lung Dis. 21 111–118. Milman N. Lisby G. Friis S. Kemp L. (2004). Prolonged culture for mycobacteria in mediastinal lymph nodes from patients with pulmonary sarcoidosis. A negative study. Sarcoidosis Vasc. Diffuse Lung Dis. 21 25–28. Milman N. Svendsen C. B. Nielsen F. C. van Overeem Hansen T. (2011). The BTNL2 A allele variant is frequent in Danish patients with sarcoidosis. Clin. Respir. J. 5 105–111. 10.1111/j.1752-699X.2010.00206.x Minshall E. M. Tsicopoulos A. Yasruel Z. Wallaert B. Akoum H. Vorng H. (1997). Cytokine mRNA gene expression in active and nonactive pulmonary sarcoidosis. Eur. Respir. J. 10 2034–2039. 10.1183/09031936.97.10092034 Mitchell D. N. Rees R. J. Goswami K. K. (1976). Transmissible agents from human sarcoid and Crohn’s disease tissues. Lancet 2 761–765. 10.1016/S0140-6736(76)90599-7 Miyara M. Amoura Z. Parizot C. Badoual C. Dorgham K. Trad S. (2006). The immune paradox of sarcoidosis and regulatory T cells. J. Exp. Med. 203 359–370. 10.1084/jem.20050648 Moller D. R. Forman J. D. Liu M. C. Noble P. W. Greenlee B. M. Vyas P. (1996). Enhanced expression of IL-12 associated with Th1 cytokine profiles in active pulmonary sarcoidosis. J. Immunol. 156 4952–4960. Morais A. Lima B. Peixoto M. J. Alves H. Marques A. Delgado L. (2012). BTNL2 gene polymorphism associations with susceptibility and phenotype expression in sarcoidosis. Respir. Med. 106 1771–1777. 10.1016/j.rmed.2012.08.009 Morandi F. Di Carlo E. Ferrone S. Petretto A. Pistoia V. Airoldi I. (2014). IL-27 in human secondary lymphoid organs attracts myeloid dendritic cells and impairs HLA class I-restricted antigen presentation. J. Immunol. 192 2634–2642. 10.4049/jimmunol.1302656 Moseley P. L. Hemken C. Monick M. Nugent K. Hunninghake G. (1986). Interferon and growth factor activity for human lung fibroblasts. Release from bronchoalveolar cells from patients with active sarcoidosis. Chest J. 89 657–662. 10.1378/chest.89.5.657 Mroz R. M. Korniluk M. Stasiak-Barmuta A. Chyczewska E. (2008). Increased levels of interleukin-12 and interleukin-18 in bronchoalveolar lavage fluid of patients with pulmonary sarcoidosis. J. Physiol. Pharmacol. 59(Suppl. 6) 507–513. Müller-Quernheim J. Prasse A. Zissel G. (2012). Pathogenesis of sarcoidosis. Presse Med. 41 275–287. 10.1016/j.lpm.2012.03.018 Negi M. Takemura T. Guzman J. Uchida K. Furukawa A. Suzuki Y. (2012). Localization of Propionibacterium acnes in granulomas supports a possible etiologic link between sarcoidosis and the bacterium. Mod. Pathol. 25 1284–1297. 10.1038/modpathol.2012.80 Newman L. S. Rose C. S. Bresnitz E. A. Rossman M. D. Barnard J. Frederick M. (2004). A case control etiologic study of sarcoidosis: environmental and occupational risk factors. Am. J. Respir. Crit. Care Med. 170 1324–1330. 10.1164/rccm.200402-249OC Nicholson T. Plant B. Henry M. Bredin C. (2010). Sarcoidosis in Ireland: regional differences in prevalence and mortality from 1996-2005. Sarcoidosis Vasc. Diffuse Lung Dis. 27 111–120. Niedbala W. Wei X. Q. Cai B. Hueber A. J. Leung B. P. McInnes I. B. (2007). IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur. J. Immunol. 37 3021–3029. 10.1002/eji.200737810 Olson B. M. Sullivan J. A. Burlingham W. J. (2013). Interleukin 35: a key mediator of suppression and the propagation of infectious tolerance. Front. Immunol. 4:315. 10.3389/fimmu.2013.00315 Oswald-Richter K. A. Beachboard D. C. Seeley E. H. Abraham S. Shepherd B. E. Jenkins C. A. (2012). Dual analysis for mycobacteria and propionibacteria in sarcoidosis BAL. J. Clin. Immunol. 32 1129–1140. 10.1007/s10875-012-9700-5 Oswald-Richter K. A. Culver D. A. Hawkins C. Hajizadeh R. Abraham S. Shepherd B. E. (2009). Cellular responses to mycobacterial antigens are present in bronchoalveolar lavage fluid used in the diagnosis of sarcoidosis. Infect. Immun. 77 3740–3348. 10.1128/IAI.00142-09 Oswald-Richter K. A. Richmond B. W. Braun N. A. Isom J. Abraham S. Taylor T. R. (2013). Reversal of global CD4+ subset dysfunction is associated with spontaneous clinical resolution of pulmonary sarcoidosis. J. Immunol. 190 5446–5453. 10.4049/jimmunol.1202891 Owaki T. Asakawa M. Fukai F. Mizuguchi J. Yoshimoto T. (2006). IL-27 induces Th1 differentiation via p38 MAPK/T-bet-and intercellular adhesion molecule-1/LFA-1/ERK1/2-dependent pathways. J. Immunol. 177 7579–7587. 10.4049/jimmunol.177.11.7579 Owaki T. Asakawa M. Morishima N. Hata K. Fukai F. Matsui M. (2005). A role for IL-27 in early regulation of Th1 differentiation. J. Immunol. 175 2191–2200. 10.4049/jimmunol.175.4.2191 Padilla M. L. Schilero G. J. Teirstein A. S. (2002). Donor-acquired sarcoidosis. Sarcoidosis Vasc. Diffuse Lung Dis. 19 18–24. Patterson K. C. Franek B. S. Muller-Quernheim J. Sperling A. I. Sweiss N. J. Niewold T. B. (2013). Circulating cytokines in sarcoidosis: phenotype-specific alterations for fibrotic and non-fibrotic pulmonary disease. Cytokine 61 906–911. 10.1016/j.cyto.2012.12.016 Patterson K. C. Hogarth K. Husain A. N. Sperling A. I. Niewold T. B. (2012). The clinical and immunologic features of pulmonary fibrosis in sarcoidosis. Trans. Res. 160 321–331. 10.1016/j.trsl.2012.03.005 Pearl J. E. Khader S. A. Solache A. Gilmartin L. Ghilardi N. Cooper A. M. (2004). IL-27 signaling compromises control of bacterial growth in mycobacteria-infected mice. J. Immunol. 173 7490–7496. 10.4049/jimmunol.173.12.7490 Pflanz S. Timans J. C. Cheung J. Rosales R. Kanzler H. Gilbert J. (2002). IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T Cells. Immunity 16 779–790. 10.1016/S1074-7613(02)00324-2 Prasse A. Georges C. Biller H. Hamm H. Matthys H. Luttmann W. (2000). Th1 cytokine pattern in sarcoidosis is expressed by bronchoalveolar CD4+ and CD8+ T cells. Clin. Exp. Immunol. 122 241–248. 10.1046/j.1365-2249.2000.01365.x Prasse A. Pechkovsky D. V. Toews G. B. Jungraithmayr W. Kollert F. Goldmann T. (2006). A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18. Am. J. Respir. Crit. Care Med. 173 781–792. 10.1164/rccm.200509-1518OC Prokop S. Heppner F. L. Goebel H. H. Stenzel W. (2011). M2 polarized macrophages and giant cells contribute to myofibrosis in neuromuscular sarcoidosis. Am. J. Pathol. 178 1279–1286. 10.1016/j.ajpath.2010.11.065 Pukiat S. McCarthy P. L. Jr. Hahn T. Morrison C. Shanahan T. Qiu J. (2011). Sarcoidosis-associated MHC Ags and the development of cutaneous and nodal granulomas following allogeneic hematopoietic cell transplant. Bone Marrow Transplant. 46 1032–1034. 10.1038/bmt.2010.235 Rappl G. Pabst S. Riemann D. Schmidt A. Wickenhauser C. Schutte W. (2011). Regulatory T cells with reduced repressor capacities are extensively amplified in pulmonary sarcoid lesions and sustain granuloma formation. Clin. Immunol. 140 71–83. 10.1016/j.clim.2011.03.015 Rastogi R. Du W. Ju D. Pirockinaite G. Liu Y. Nunez G. (2011). Dysregulation of p38 and MKP-1 in response to NOD1/TLR4 stimulation in sarcoid bronchoalveolar cells. Am. J. Respir. Crit. Care Med. 183 500–510. 10.1164/rccm.201005-0792OC Richmond B. W. Ploetze K. Isom J. Chambers-Harris I. Braun N. A. Taylor T. (2013). Sarcoidosis Th17 cells are ESAT-6 antigen specific but demonstrate reduced IFN-gamma expression. J. Clin. Immunol. 33 446–55. 10.1007/s10875-012-9817-6 Robinson B. McLemore T. L. Crystal R. G. (1985). Gamma interferon is spontaneously released by alveolar macrophages and lung T lymphocytes in patients with pulmonary sarcoidosis. J. Clin. Investig. 75 1488–1495. 10.1172/JCI111852 Rogge L. Papi A. Presky D. H. Biffi M. Minetti L. J. Miotto D. (1999). Antibodies to the IL-12 receptor beta 2 chain mark human Th1 but not Th2 cells in vitro and in vivo. J. Immunol. 162 3926–3932. Rybicki B. A. Iannuzzi M. C. (eds). (2007). “Epidemiology of sarcoidosis: recent advances and future prospects,” in Seminars in Respiratory and Critical Care Medicine (New York: Thieme Medical Publishers). Rybicki B. A. Iannuzzi M. C. Frederick M. M. Thompson B. W. Rossman M. D. Bresnitz E. A. (2001). Familial aggregation of sarcoidosis: a case–control etiologic study of sarcoidosis (ACCESS). Am. J. Respir. Crit. Care Med. 164 2085–2091. 10.1164/ajrccm.164.11.2106001 Salazar A. Mana J. Fiol C. Hurtado I. Argimon J. M. Pujol R. (2000). Influence of serum amyloid a on the decrease of high density lipoprotein-cholesterol in active sarcoidosis. Atherosclerosis 152 497–502. 10.1016/S0021-9150(00)00368-3 Sato H. Woodhead F. A. Ahmad T. Grutters J. C. Spagnolo P. van den Bosch J. M. (2010). Sarcoidosis HLA class II genotyping distinguishes differences of clinical phenotype across ethnic groups. Hum. Mol. Genet. 19 4100–4111. 10.1093/hmg/ddq325 Seyerl M. Kirchberger S. Majdic O. Seipelt J. Jindra C. Schrauf C. (2010). Human rhinoviruses induce IL–35-producing treg via induction of B7–H1 (CD274) and sialoadhesin (CD169) on DC. Eur. J. Immunol. 40 321–329. 10.1002/eji.200939527 Shigehara K. Shijubo N. Ohmichi M. Kamiguchi K. Takahashi R. Morita-Ichimura S. (2003). Increased circulating interleukin-12 (IL-12) p40 in pulmonary sarcoidosis. Clin. Exp. Immunol. 132 152–157. 10.1046/j.1365-2249.2003.02105.x Shigehara K. Shijubo N. Ohmichi M. Takahashi R. Kon S. Okamura H. (2001). IL-12 and IL-18 are increased and stimulate IFN-gamma production in sarcoid lungs. J. Immunol. 166 642–649. 10.4049/jimmunol.166.1.642 Song G. G. Kim J. H. Lee Y. H. (2014). Associations between TNF-α- 308 A/G and lymphotoxin-α+ 252 A/G polymorphisms and susceptibility to sarcoidosis: a meta-analysis. Mol. Biol. Rep. 41 259–267. 10.1007/s11033-013-2859-x Spagnolo P. Grunewald J. (2013). Recent advances in the genetics of sarcoidosis. J. Med. Genet. 50 290–297. 10.1136/jmedgenet-2013-101532 Spagnolo P. Sato H. Grutters J. C. Renzoni E. A. Marshall S. E. Ruven H. J. (2007). Analysis of BTNL2 genetic polymorphisms in British and Dutch patients with sarcoidosis. Tissue Antigens 70 219–227. 10.1111/j.1399-0039.2007.00879.x Stoll S. Jonuleit H. Schmitt E. Müller G. Yamauchi H. Kurimoto M. (1998). Production of functional IL-18 by different subtypes of murine and human dendritic cells (DC): DC-derived IL-18 enhances IL-12-dependent Th1 development. Eur. J. Immunol. 28 3231–3239. 10.1002/(SICI)1521-4141(199810)28:10<3231::AID-IMMU3231>3.0.CO;2-Q Stumhofer J. S. Silver J. S. Laurence A. Porrett P. M. Harris T. H. Turka L. A. (2007). Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. Nat. Immunol. 8 1363–1371. 10.1038/ni1537 Suzuki H. Ota M. Meguro A. Katsuyama Y. Kawagoe T. Ishihara M. (2012). Genetic characterization and susceptibility for sarcoidosis in Japanese patients: risk factors of BTNL2 gene polymorphisms and HLA class II alleles. Investig. Ophthalmolol. Vis. Sci. 53 7109–7115. 10.1167/iovs.12-10491 Sweeney C. M. Lonergan R. Basdeo S. A. Kinsella K. Dungan L. S. Higgins S. C. (2011). IL-27 mediates the response to IFN-beta therapy in multiple sclerosis patients by inhibiting Th17 cells. Brain Behav. Immun. 25 1170–1181. 10.1016/j.bbi.2011.03.007 Taflin C. Miyara M. Nochy D. Valeyre D. Naccache J. M. Altare F. (2009). FoxP3+ regulatory T cells suppress early stages of granuloma formation but have little impact on sarcoidosis lesions. Am. J. Pathol. 174 497–508. 10.2353/ajpath.2009.080580 Taha R. A. Minshall E. M. Olivenstein R. Ihaku D. Wallaert B. Tsicopoulos A. (1999). Increased expression of IL-12 receptor mRNA in active pulmonary tuberculosis and sarcoidosis. Am. J. Respir. Crit. Care Med. 160 1119–1123. 10.1164/ajrccm.160.4.9807120 Takemori N. Nakamura M. Kojima M. Eishi Y. (2014). Successful treatment in a case of Propionibacterium acnes-associated sarcoidosis with clarithromycin administration: a case report. J. Med. Case Rep. 8 15. 10.1186/1752-1947-8-15 Ten Berge B. Paats M. S. Bergen I. M. van den Blink B. Hoogsteden H. C. Lambrecht B. N. (2012). Increased IL-17A expression in granulomas and in circulating memory T cells in sarcoidosis. Rheumatology (Oxford) 51 37–46. 10.1093/rheumatology/ker316 Terasaki F. Ukimura A. Tsukada B. Fujita S. Katashima T. Otsuka K. (2008). Enhanced expression of type 1 helper T-cell cytokines in the myocardium of active cardiac sarcoidosis. Circ. J. 72 1303–1307. 10.1253/circj.72.1303 Terčelj M. Rott T. Rylander R. (2007). Antifungal treatment in sarcoidosis–a pilot intervention trial. Respir. Med. 101 774–778. 10.1016/j.rmed.2006.08.005 Terčelj M. Salobir B. Zupancic M. Rylander R. (2011a). Antifungal medication is efficient in the treatment of sarcoidosis. Ther. Adv. Respir. Dis. 5 157–162. 10.1177/1753465811401648 Terčelj M. Salobir B. Harlander M. Rylander R. (2011b). Fungal exposure in homes of patients with sarcoidosis-an environmental exposure study. Environ. Health 10 8. 10.1186/1476-069X-10-8 Terčelj M. Salobir B. Zupancic M. Wraber B. Rylander R. (2013). Inflammatory markers and pulmonary granuloma infiltration in sarcoidosis. Respirology 19 225–230. 10.1111/resp.12199 Urbankowski T. Hoser G. Domagala-Kulawik J. (2012). Th1/Th2/Th17related cytokines in the bronchoalveolar lavage fluid of patients with sarcoidosis: association with smoking. Pol. Arch. Med . Wewn. 122 320–325. Vasakova M. Sterclova M. Kolesar L. Slavcev A. Skibova J. Striz I. (2010). Cytokine gene polymorphisms in sarcoidosis. Sarcoidosis Vasc. Diffuse Lung Dis. 27 70–75. Veltkamp M. Van Moorsel C. H. Rijkers G. T. Ruven H. J. Van Den Bosch J. M. Grutters J. C. (2010). Toll-like receptor (TLR)-9 genetics and function in sarcoidosis. Clin. Exp. Immunol. 162 68–74. 10.1111/j.1365-2249.2010.04205.x Veltkamp M. Wijnen P. A. van Moorsel C. H. Rijkers G. T. Ruven H. J. Heron M. (2007). Linkage between toll-like receptor (TLR) 2 promotor and intron polymorphisms: functional effects and relevance to sarcoidosis. Clin. Exp. Immunol. 149 453–462. 10.1111/j.1365-2249.2007.03428.x Vignali D. A. Kuchroo V. K. (2012). IL-12 family cytokines: immunological playmakers. Nat. Immunol. 13 722–728. 10.1038/ni.2366 Villarino A. Hibbert L. Lieberman L. Wilson E. Mak T. Yoshida H. (2003). The IL-27R (WSX-1) is required to suppress T cell hyperactivity during infection. Immunity 19 645–655. 10.1016/S1074-7613(03)00300-5 Volpe E. Servant N. Zollinger R. Bogiatzi S. I. Hupe P. Barillot E. (2008). A critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses. Nat. Immunol. 9 9650–9657. 10.1038/ni.1613 Wahlstrom J. Dengjel J. Persson B. Duyar H. Rammensee H. G. Stevanovic S. (2007). Identification of HLA-DR-bound peptides presented by human bronchoalveolar lavage cells in sarcoidosis. J. Clin. Investig. 117 3576–3582. 10.1172/JCI32401 Wahlstrom J. Dengjel J. Winqvist O. Targoff I. Persson B. Duyar H. (2009). Autoimmune T cell responses to antigenic peptides presented by bronchoalveolar lavage cell HLA-DR molecules in sarcoidosis. Clin. Immunol. 133 353–363. 10.1016/j.clim.2009.08.008 Wang R. X. Yu C. R. Dambuza I. M. Mahdi R. M. Dolinska M. B. Sergeev Y. V. (2014). Interleukin-35 induces regulatory B cells that suppress autoimmune disease. Nat. Med. 20 633–641. 10.1038/nm.3554 Wennerstrom A. Pietinalho A. Vauhkonen H. Lahtela L. Palikhe A. Hedman J. (2012). HLA-DRB1 allele frequencies and C4 copy number variation in Finnish sarcoidosis patients and associations with disease prognosis. Hum. Immunol. 73 93–100. 10.1016/j.humimm.2011.10.016 Whitehead G. S. Wilson R. H. Nakano K. Burch L. H. Nakano H. Cook D. N. (2012). IL-35 production by inducible costimulator (ICOS)-positive regulatory T cells reverses established IL-17-dependent allergic airways disease. J. Allergy Clin. Immunol. 129 207-15.e1–207-15.e5. 10.1016/j.jaci.2011.08.009 Wijnen P. A. Cremers J. P. Nelemans P. J. Erckens R. J. Hoitsma E. Jansen T. L. (2014). Association of the TNF-α G-308A polymorphism with TNF-inhibitor response in sarcoidosis. Eur. Respir. J. 43 1730–1739. 10.1183/09031936.00169413 Wijnen P. A. Nelemans P. J. Verschakelen J. A. Bekers O. Voorter C. E. Drent M. (2010). The role of tumor necrosis factor alpha G-308A polymorphisms in the course of pulmonary sarcoidosis. Tissue Antigens 75 262–268. 10.1111/j.1399-0039.2009.01437.x Wijnen P. A. Voorter C. E. Nelemans P. J. Verschakelen J. A. Bekers O. Drent M. (2011). Butyrophilin-like 2 in pulmonary sarcoidosis: a factor for susceptibility and progression? Hum. Immunol. 72 342–347. 10.1016/j.humimm.2011.01.011 Wikén M. Idali F. Al Hayja M. A. Grunewald J. Eklund A. Wahlström J. (2010). No evidence of altered alveolar macrophage polarization, but reduced expression of TLR2, in bronchoalveolar lavage cells in sarcoidosis. Respir. Res. 11 121–133. 10.1186/1465-9921-11-121 Wilson N. J. Boniface K. Chan J. R. McKenzie B. S. Blumenschein W. M. Mattson J. D. (2007). Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat. Immunol. 8 950–957. 10.1038/ni1497 Ye S. Wu J. Zhou L. Lv Z. Xie H. Zheng S. (2013). Interleukin-35: the future of hyperimmune-related diseases? J. Interferon Cytokine Res. 33 285–291. 10.1089/jir.2012.0086 Yoshimoto T. Takeda K. Tanaka T. Ohkusu K. Kashiwamura S. Okamura H. (1998). IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-γ production. J. Immunol. 161 3400–3407. Zeitvogel J. Werfel T. Wittmann M. (2012). IL-27 acts as a priming signal for IL-23 but not IL-12 production on human antigen-presenting cells. Exp. Dermatol. 21 426–430. 10.1111/j.1600-0625.2012.01484.x Zhang Y. Chen X. Hu Y. Du S. Shen L. He Y. (2013). Preliminary characterizations of a serum biomarker for sarcoidosis by comparative proteomic approach with tandem-mass spectrometry in ethnic Han Chinese patients. Respir. Res. 14 18. 10.1186/1465-9921-14-18 Zhou Y. Shen L. Zhang Y. Jiang D. Li H. (2011). Human leukocyte antigen-A, -B, and -DRB1 alleles and sarcoidosis in Chinese Han subjects. Hum. Immunol. 72 571–575. 10.1016/j.humimm.2011.03.020 Zissel G. Homolka J. Schlaak J. Schlaak M. Müller-Quernheim J. (1996). Anti-inflammatory cytokine release by alveolar macrophages in pulmonary sarcoidosis. Am. J. Respir. Crit. Care Med. 154 713–719. 10.1164/ajrccm.154.3.8810610